Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology

54Citations
Citations of this article
156Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Functional gastrointestinal disorders (FGIDs) are common and distressing. They are so named because a defined pathophysiology in terms of structural or biochemical pathways is lacking. Traditionally FGIDs have been conceptualized as brain–gut disorders, with subgroups of patients demonstrating visceral hypersensitivity and motility abnormalities as well as psychological distress. However, it is becoming apparent that there are certain structural or biochemical gut alterations among subsets with the common FGIDs, most notably functional dyspepsia (FD) and irritable bowel syndrome (IBS). For example, a sodium channel mutation has been identified in IBS that may account for 2 % of cases, and subtle intestinal inflammation has been observed in both IBS and FD. Other research has implicated early life events and stress, autoimmune disorders and atopy and infections, the gut microbiome and disordered mucosal immune activation in patients with IBS or FD. Understanding the origin of symptoms in FGIDs will allow therapy to be targeted at the pathophysiological changes, not at merely alleviating symptoms, and holds hope for eventual cure in some cases. For example, there are promising developments in manipulating the microbiome through diet, prebiotics and antibiotics in IBS, and testing and treating patients for Helicobacter pylori infection remains a mainstay of therapy in patients with dyspepsia and this infection. Locally acting drugs such as linaclotide have been an advance in treating the symptoms of constipation-predominant IBS, but do not alter the natural history of the disease. A role for a holistic approach to patients with FGIDs is warranted, as brain-to-gut and gut-to-brain pathways appear to be activated.

References Powered by Scopus

Functional Bowel Disorders

4195Citations
N/AReaders
Get full text

Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis

1635Citations
N/AReaders
Get full text

The role of the gut microbiota in nutrition and health

1554Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Pathophysiology of irritable bowel syndrome

428Citations
N/AReaders
Get full text

Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study

247Citations
N/AReaders
Get full text

The nutritional and health attributes of kiwifruit: a review

243Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Talley, N. J., Holtmann, G., & Walker, M. M. (2015, June 10). Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology. Journal of Gastroenterology. Springer Tokyo. https://doi.org/10.1007/s00535-015-1076-x

Readers over time

‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2507142128

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 37

57%

Researcher 14

22%

Professor / Associate Prof. 9

14%

Lecturer / Post doc 5

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 40

56%

Nursing and Health Professions 13

18%

Biochemistry, Genetics and Molecular Bi... 11

15%

Agricultural and Biological Sciences 8

11%

Article Metrics

Tooltip
Mentions
News Mentions: 1
Social Media
Shares, Likes & Comments: 2

Save time finding and organizing research with Mendeley

Sign up for free
0